Drug intelligence / Profile preview

iNK013

Development stage: Preclinical
Lead developer: Cell Inspire Biotechnology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

iNK013 is an induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy developed by Cell Inspire Biotechnology. The therapy consists of NK cells engineered to express CD16 (FcγRIIIa) and a secreted form of interleukin-15 (sIL-15). The expression of CD16 is intended to enhance antibody-dependent cellular cytotoxicity (ADCC) when used in combination with monoclonal antibodies, while the secretion of IL-15 is designed to increase the persistence, proliferation, and anti-tumor activity of the NK cells within the tumor microenvironment. iNK013 is currently in preclinical development for the treatment of various cancers.

Targets

FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on iNK013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iNK013.

Explore the full profile